April Kelly Scott Salama, MD

Publications

Ott, PA, Pavlick, AC, Johnson, DB, Hart, LL, Infante, JR, Luke, JJ, Lutzky, J, Rothschild, NE, Spitler, LE, Cowey, CL, Alizadeh, AR, Salama, AK, He, Y, Hawthorne, TR, Bagley, RG, Zhang, J, Turner, CD, and Hamid, O. "A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma." Cancer (January 28, 2019).

PMID
30690710
Full Text

Kwak, M, Farrow, NE, Salama, AKS, Mosca, PJ, Hanks, BA, Slingluff, CL, and Beasley, GM. "Updates in adjuvant systemic therapy for melanoma." Journal of Surgical Oncology 119, no. 2 (January 2019): 222-231. (Review)

PMID
30481375
Full Text

Puza, CJ, Bressler, ES, Terando, AM, Howard, JH, Brown, MC, Hanks, B, Salama, AKS, and Beasley, GM. "The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy." The Journal of Surgical Research 236 (December 20, 2018): 209-215.

PMID
30694757
Full Text

Tan, I, Malinzak, M, and Salama, AKS. "Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy." Journal for Immunotherapy of Cancer 6, no. 1 (July 31, 2018): 77-null.

PMID
30064495
Full Text

Sammons, S, McNamara, M, Salama, AKS, and Crawford, J. "Immune checkpoint inhibition." In Side Effects of Medical Cancer Therapy: Prevention and Treatment: Second Edition, 315-353. June 27, 2018.

Full Text

Barker, CA, and Salama, AK. "New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma." Journal of the National Comprehensive Cancer Network : Jnccn 16, no. 5S (May 2018): 646-650.

PMID
29784747
Full Text

Maio, M, Lewis, K, Demidov, L, Mandalà, M, Bondarenko, I, Ascierto, PA, Herbert, C, Mackiewicz, A, Rutkowski, P, Guminski, A, Goodman, GR, Simmons, B, Ye, C, Yan, Y, Schadendorf, D, Cinat, G, Fein, LE, Brown, M, Haydon, A, Khattak, A, McNeil, C, Parente, P, Power, J, Roberts-Thomson, R, Sandhu, S, Underhill, C, Varma, S, Berger, T, Awada, A, Blockx, N, Buyse, V, Mebis, J, Franke, FA, Jobim de Azevedo, S, Silva Lazaretti, N, Jamal, R, Mihalcioiu, C, Petrella, T, Savage, K, Song, X, Wong, R, Dabelic, N, Plestina, S, Vojnovic, Z, Arenberger, P, Kocak, I, Krajsova, I, Kubala, E, Melichar, B, Vantuchova, Y, Putnik, K, Dreno, B, Dutriaux, C, Grob, JJ, Joly, P, Lacour, JP, Meyer, N, Mortier, L, Thomas, L, Fluck, M, Gambichler, T, Hassel, J, Hauschild, A, Donnellan, P, McCaffrey, J, Power, D, Ariad, S, Bar-Sela, G, Hendler, D, Ron, I, Schachter, J, Ascierto, P, Berruti, A, Bianchi, L, Chiarion Sileni, V, Cognetti, F, Danielli, R, Di Giacomo, AM, Gianni, L, Goldhirsch, A, Guida, M, Marchetti, P, Queirolo, P, Santoro, A, Kapiteijn, E, Ferreira, P, Gafton, G, Makarova, Y, Andric, Z, Babovic, N, Jovanovic, D, and Kandolf Sekulovic, L. "Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial." The Lancet Oncology 19, no. 4 (April 1, 2018): 510-520.

Full Text

Clarke, JM, George, DJ, Lisi, S, and Salama, AKS. "Immune Checkpoint Blockade: The New Frontier in Cancer Treatment." Targeted oncology 13, no. 1 (February 13, 2018): 1-20.

PMID
29441437
Full Text

Bhatti, MT, and Salama, AKS. "Neuro-ophthalmic side effects of molecularly targeted cancer drugs." Eye (London, England) 32, no. 2 (February 2018): 287-301. (Review)

PMID
29052609
Full Text

Hamid, O, Puzanov, I, Dummer, R, Schachter, J, Daud, A, Schadendorf, D, Blank, C, Cranmer, LD, Robert, C, Pavlick, AC, Gonzalez, R, Hodi, FS, Ascierto, PA, Salama, AKS, Margolin, KA, Gangadhar, TC, Wei, Z, Ebbinghaus, S, Ibrahim, N, and Ribas, A. "Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma." European Journal of Cancer (Oxford, England : 1990) 86 (November 2017): 37-45.

PMID
28961465
Full Text

Pages